Suppr超能文献

患者年龄和供者 HLA 匹配可将异基因造血细胞移植患者分层为预后组。

Patient age and donor HLA matching can stratify allogeneic hematopoietic cell transplantation patients into prognostic groups.

机构信息

Hans Messner Allogeneic Transplant Program, Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada.

Department of Oncology, Juravinski Cancer Centre, Hamilton Health Sciences, McMaster University, Hamilton, Ontario, Canada.

出版信息

Eur J Haematol. 2022 Dec;109(6):672-679. doi: 10.1111/ejh.13850. Epub 2022 Sep 10.

Abstract

BACKGROUND

Mixed results surround the accuracy of commonly used prognostic risk scores to predict overall survival (OS) and non-relapse mortality (NRM) in allogeneic hematopoietic stem cell transplant (allo-HCT) recipients. We hypothesize that a simple prognostic score performs better than conventional scoring systems.

PATIENTS AND METHODS

OS risk factors, HCT-CI, age-HCT-CI, and augmented-HCT-CI were studied in 299 patients who underwent allo-HCT for myeloid and lymphoid malignancies. A scoring system was developed based on results and validated in a different cohort of 455 patients.

RESULTS

Two-year OS was 51% (95% confidence interval (CI) 0.45-0.56); 2-year NRM was 34% (95% CI 0.29-0.39). HCT-CI and associated scores were grouped into 0-2 and ≥3. Age and HLA mismatch status were the only risk factors to affect OS in multivariate analysis (p = 0.02 and 0.05, respectively). HCT-CI and associated scores were not informative for OS prediction. The weighted scoring system assigned 0 to 2 points for age < 50, 50-64, or ≥65, respectively, and 0-1 points for no HLA mismatch versus any mismatch (except HLA-DQ). Distinct 2-year OS (62%, 53%, and 38% [p = <0.001]) and NRM (24%, 34%, and 43% [p = 0.02]) groups were characterized. The scoring system was validated in a second independent cohort with similar results on OS and NRM (p < 0.001).

CONCLUSIONS

A simple scoring system based on recipient's age and mismatch status accurately predict OS and NRM in two distinct cohorts of allo-HCT patients. Its simplicity makes it a helpful tool to aid clinicians and patients in clinical decision-making.

摘要

背景

常用的预后风险评分在预测异基因造血干细胞移植(allo-HCT)受者的总生存(OS)和非复发死亡率(NRM)方面的准确性存在差异。我们假设一个简单的预后评分比传统的评分系统表现更好。

患者和方法

我们研究了 299 例接受allo-HCT 治疗骨髓和淋巴恶性肿瘤的患者的 OS 风险因素、HCT-CI、年龄-HCT-CI 和增强-HCT-CI。基于结果建立了一个评分系统,并在另一组 455 例患者中进行了验证。

结果

2 年 OS 率为 51%(95%置信区间[CI] 0.45-0.56);2 年 NRM 率为 34%(95%CI 0.29-0.39)。在多变量分析中,HCT-CI 和相关评分被分为 0-2 分和≥3 分。年龄和 HLA 错配状态是唯一影响 OS 的危险因素(p=0.02 和 0.05)。HCT-CI 和相关评分对 OS 预测没有信息。加权评分系统将年龄<50、50-64 和≥65 分别赋值为 0-2 分,无 HLA 错配与任何错配(除 HLA-DQ 外)分别赋值为 0-1 分。不同的 2 年 OS(62%、53%和 38%[p<0.001])和 NRM(24%、34%和 43%[p=0.02])组具有特征性。该评分系统在第二个独立队列中得到验证,OS 和 NRM 结果相似(p<0.001)。

结论

基于受者年龄和错配状态的简单评分系统在两个独立的 allo-HCT 患者队列中准确预测 OS 和 NRM。其简单性使其成为辅助临床医生和患者进行临床决策的有用工具。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验